Blood biomarkers predicting adverse clinical outcomes in congenital heart disease patients, with consideration for pulmonary valve replacement

1 Søndergaard Lars. Early Versus Later Re-valving in Tetralogy of Fallot with Free Pulmonary Regurgitation. 2019 May;(5th Edition). Available from: https://www.clinicaltrials.gov/ProvidedDocs/32/NCT04084132/Prot_SAP_000.pdf Search in Google Scholar

2 Westhoff-Bleck M, Kornau F, Haghikia A, Horke A, Bertram H, Treptau J, et al. NT-proBNP Indicates Left Ventricular Impairment and Adverse Clinical Outcome in Patients With Tetralogy of Fallot and Pulmonary Regurgitation. Can J Cardiol. 2016 Oct;32(10):1247.e29-1247.e36. Search in Google Scholar

3 Villafañe J, Feinstein JA, Jenkins KJ, Vincent RN, Walsh EP, Dubin AM, et al. Hot Topics in Tetralogy of Fallot. J Am Coll Cardiol. 2013 Dec;62(23):2155–66. Search in Google Scholar

4 Downing TE, Kim YY. Tetralogy of Fallot. Cardiol Clin. 2015 Nov;33(4):531–41. Search in Google Scholar

5 Bhagra CJ, Hickey EJ, Van De Bruaene A, Roche SL, Horlick EM, Wald RM. Pulmonary Valve Procedures Late After Repair of Tetralogy of Fallot: Current Perspectives and Contemporary Approaches to Management. Can J Cardiol. 2017 Sep;33(9):1138–49. Search in Google Scholar

6 Heng EL. Improved outcome prediction in tetralogy of Fallot. 2016 Dec [cited 2022 Jul 12]; Available from: http://spiral.imperial.ac.uk/handle/10044/1/50676 Search in Google Scholar

7 Zegelbone PM, Ringel RE, Coulson JD, Nies MK, Stabler ME, Brown JR, et al. Heart failure biomarker levels correlate with invasive haemodynamics in pulmonary valve replacement. Cardiol Young. 2020 Jan;30(1):50–4. Search in Google Scholar

8 van der Ven JPG, van den Bosch E, Bogers AJCC, Helbing WA. Current outcomes and treatment of tetralogy of Fallot. F1000Research. 2019;8:F1000 Faculty Rev-1530. Search in Google Scholar

9 Nawaytou H, Bernstein HS. Biomarkers in pediatric heart disease. Biomark Med. 2014 Aug;8(7):943–63. Search in Google Scholar

10 Peng EWK, Spooner R, Young D, Danton MHD. Acute B-type natriuretic peptide response and early postoperative right ventricular physiology following tetralogy of Fallot’s repair. Interact Cardiovasc Thorac Surg. 2012 Sep 1;15(3):335–9. Search in Google Scholar

11 Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW. The Usefulness of Brain Natriuretic Peptide in Complex Congenital Heart Disease. J Am Coll Cardiol. 2012 Nov;60(21):2140–9. Search in Google Scholar

12 Jabagi H, Mielniczuk LM, Liu PP, Ruel M, Sun LY. Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery—Are We There Yet? J Clin Med. 2019 Apr 25;8(4):559. Search in Google Scholar

13 Cantinotti M, Law Y, Vittorini S, Crocetti M, Marco M, Murzi B, et al. The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update. Heart Fail Rev. 2014 Nov;19(6):727–42. Search in Google Scholar

14 Cantinotti M, Walters HL, Crocetti M, Marotta M, Murzi B, Clerico A. BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use? Cardiol Young. 2015 Mar;25(3):424–37. Search in Google Scholar

15 S.E. Luijnenburg. Outcome Late After Repair of Tetralogy of Fallot [Internet]. Available from: https://repub.eur.nl/pub/40677/ Search in Google Scholar

16 Dobson R, Walker HA, Walker NL. Biomarkers in congenital heart disease. Biomark Med. 2014 Aug;8(7):965–75. Search in Google Scholar

17 Willinger L, Brudy L, Meyer M, Oberhoffer-Fritz R, Ewert P, Müller J. Prognostic value of non-acute high sensitive troponin-T for cardiovascular morbidity and mortality in adults with congenital heart disease: A systematic review. J Cardiol. 2021 Sep;78(3):206–12. Search in Google Scholar

18 Hirono K, Sekine M, Shiba N, Hayashi S, Nakaoka H, Ibuki K, et al. N-terminal pro-Brain Natriuretic Peptide as a Predictor of Reoperation in Children With Surgically Corrected Tetralogy of Fallot. Circ J. 2014;78(3):693–700. Search in Google Scholar

19 Nir A, Luchner A, Rein AJ. The natriuretic peptides as biomarkers for adults with congenital heart disease. Biomark Med. 2012 Dec;6(6):827–37. Search in Google Scholar

20 Heng EL, Bolger AP, Kempny A, Davlouros PA, Davidson S, Swan L, et al. Neurohormonal activation and its relation to outcomes late after repair of tetralogy of Fallot. Heart. 2015 Mar 15;101(6):447–54. Search in Google Scholar

21 Paolino A, Hussain T, Pavon A, Velasco MN, Uribe S, Ordoñez A, et al. NT-proBNP as Marker of Ventricular Dilatation and Pulmonary Regurgitation After Surgical Correction of Tetralogy of Fallot: A MRI Validation Study. Pediatr Cardiol. 2017 Feb;38(2):324–31. Search in Google Scholar

22 Eindhoven JA, Menting ME, van den Bosch AE, Cuypers JAAE, Ruys TPE, Witsenburg M, et al. Associations between N-terminal pro-B-type natriuretic peptide and cardiac function in adults with corrected tetralogy of Fallot. Int J Cardiol. 2014 Jul;174(3):550–6. Search in Google Scholar

23 Schoonbeek RC, Pieper PG, van Slooten YJ, Freling HG, Sieswerda GT, van Dijk APJ, et al. NT-proBNP and exercise capacity in adult patients with congenital heart disease and a prosthetic valve: a multicentre PROSTAVA study. Neth Heart J. 2016 Nov;24(11):653–65. Search in Google Scholar

24 Baggen VJM, van den Bosch AE, Eindhoven JA, Schut ARW, Cuypers JAAE, Witsenburg M, et al. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease. Circulation. 2017 Jan 17;135(3):264–79. Search in Google Scholar

25 Rajpal S, Alshawabkeh L, Opotowsky AR. Current Role of Blood and Urine Biomarkers in the Clinical Care of Adults with Congenital Heart Disease. Curr Cardiol Rep. 2017 Jun;19(6):50. Search in Google Scholar

26 Yasukawa T, Hoashi T, Imai K, Okuda N, Fukuda T, Ohuchi H, et al. The reduced left ventricular stroke volume does not fully recover after pulmonary valve replacement in patients with repaired tetralogy of Fallot. Eur J Cardiothorac Surg. 2021 Sep 11;60(3):526–33. Search in Google Scholar

27 Kitagawa A, Oka N, Kimura S, Ando H, Honda T, Takanashi M, et al. Clinical Utility of the Plasma Brain Natriuretic Peptide Level in Monitoring Tetralogy of Fallot Patients over the Long Term After Initial Intracardiac Repair: Considerations for Pulmonary Valve Replacement. Pediatr Cardiol. 2015 Apr;36(4):752–8. Search in Google Scholar

28 Kapoor PM, Subramanian A, Malik V, Kiran U, Velayoudham D. B-type natriuretic peptide as prognostic marker in tetralogy of Fallot surgery. Asian Cardiovasc Thorac Ann. 2015 Feb;23(2):146–52. Search in Google Scholar

29 Khokhar A, Zuhair M, Raj B, Heng EL, Alonso-Gonzalez R, Kempny A, et al. 2109Predictors of mortality following hospitalisation in adults with congenital heart disease. Eur Heart J [Internet]. 2018 Aug 1 [cited 2022 Aug 26];39(suppl_1). Available from: https://academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehy565.2109/5082713 Search in Google Scholar

30 Alborikan S, Von Klemperer K, Bhan A, Walker F, Pandya B, Badiani S, et al. Blood biomarkers in patients with repaired Tetralogy of Fallot (rTOF); A systematic review and meta-analysis. Int J Cardiol Congenit Heart Dis. 2021 Dec;6:100237. Search in Google Scholar